Abstract
BackgroundPatients (pts) with PsA experience significant impairment of work productivity (WP) and health-related QoL (HRQoL). Secukinumab (SEC) has previously been shown to rapidly improve symptoms, physical function and HRQoL in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have